Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | XIAP | P98170 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297455 | 0.92 | ELANE (0.40) | RENELANEXIAPCMA1MLX | |
| SCHEMBL29463845 | 0.92 | ELANE (0.42) | RENELANEXIAPCMA1MLX | |
| SCHEMBL21581232 | 0.92 | ELANE (0.42) | RENELANEXIAPCMA1MLX | |
| SCHEMBL17029371 | 0.92 | ELANE (0.40) | RENELANEXIAPCMA1MLX | |
| SCHEMBL10297438 | 0.92 | ELANE (0.42) | RENELANEXIAPCMA1MLX | |
| SCHEMBL10297429 | 0.92 | ELANE (0.40) | RENELANEXIAPCMA1MLX | |
| SCHEMBL10297466 | 0.92 | ELANE (0.42) | RENELANEXIAPCMA1MLX | |
| SCHEMBL10297439 | 0.90 | REN (0.44) | RENAPLNRCMA1 | |
| SCHEMBL10297425 | 0.90 | REN (0.44) | RENF2F10PRSS1PLG | |
| SCHEMBL17029372 | 0.90 | REN (0.44) | RENF2F10PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | disclosed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | disclosed |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | Ela Pharma Ltd (IL) | 2024-04-02 | — | — | US | disclosed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| CN-107690429-B | Composition for the treatment and/or prevention of necrosis of cells or tissue, specifically targeting cathepsin C and/or CELA1 and/or CELA3A and/or enzymes structurally related thereto | ELA制药有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | REN 780/4885ELANE 36/4885XIAP 144/4885 |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSA, CPA1 | REN 1057/4885ELANE 118/4885XIAP 1373/4885 |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | REN 780/4885ELANE 36/4885XIAP 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.